Lake Street Capital lowered its shares of Brickell Biotech (NASDAQ: BBI – Get Rating) from a purchase valuation to a retention valuation in a research note published Friday morning, The Fly reports.
Several other research firms have also recently commented on BBI. William Blair began hedging Brickell Biotech’s stock in a research note on Tuesday, March 8. They have established an outperforming rating on the stock. HC Wainwright began hedging the shares of Brickell Biotech in a research note on Tuesday, Jan.18. They have established a buy valuation and a $ 2.00 target price on the stock. Finally, Zacks Investment Research cut the shares of Brickell Biotech from a buy rating to a maintenance rating in a research note Tuesday.
Shares of BBI stock fell $ 0.02 during trading hours Friday, reaching $ 0.19. The stock had a trading volume of 5,847,425 shares, compared to its average volume of 11,037,573. Brickell Biotech has a twelve-month low of $ 0.19 and a twelve-month high of $ 1.04. The company has a 50-day simple moving average of $ 0.26 and a 200-day simple moving average of $ 0.27.
Brickell Biotech (NASDAQ: BBI – Get Rating) last released its quarterly earnings data on Thursday, May 12. The company reported ($ 0.08) earnings per share for the quarter, missing analyst consensus estimates of ($ 0.06) of ($ 0.02). Brickell Biotech had a negative return on equity of 163.84% and a negative net margin of 9,770.79%. During the same quarter last year, the company reported earnings per share ($ 0.15). Equity analysts expect Brickell Biotech to post EPS -0.2 for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in BBI. Morgan Stanley increased its holdings in Brickell Biotech stock by 142.0% in the first quarter. Morgan Stanley now owns 75,404 shares of the company worth $ 82,000 after purchasing an additional 44,248 shares during the period. Citadel Advisors LLC acquired a new equity interest in Brickell Biotech during the second quarter worth approximately $ 76,000. BlackRock Inc. increased its holdings in Brickell Biotech stock by 69.2% during the third quarter. BlackRock Inc. now owns 63,544 shares of the company worth $ 46,000 after purchasing an additional 25,985 shares during the period. Geode Capital Management LLC increased its holdings in Brickell Biotech stock by 11.4% during the third quarter. Geode Capital Management LLC now owns 627,294 shares in the company worth $ 451,000 after purchasing an additional 63,982 shares during the period. Finally, GSA Capital Partners LLP acquired a new equity interest in Brickell Biotech during the third quarter valued at approximately $ 179,000. Institutional investors own 14.99% of the company’s shares.
About Brickell Biotech (Get evaluation)
Brickell Biotech, Inc, a clinical stage pharmaceutical company, is engaged in the development of various prescription drugs for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironio bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent interferon gene inhibitor stimulator for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.
Get news and ratings for Brickell Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Brickell Biotech and related companies with MarketBeat.com’s FREE daily newsletter.